Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05645523 · ClinicalTrials.gov registry record · Early Phase 1
Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors
A Early Phase 1 study of Solid Tumor, sponsored by St. Jude Children's Research Hospital.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 25
- Enrollment target
- 3
- Study locations
NCT05645523: Recruiting Early Phase 1 study of Solid Tumor, sponsored by St. Jude Children's Research Hospital.
NCT05645523 is a Early Phase 1 study of Solid Tumor that is actively recruiting participants, run by St. Jude Children's Research Hospital. The registered enrollment target is 25 participants, below the 222-participant average among 196 other Solid Tumor trials with a reported enrollment target (89% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05645523, a Early Phase 1 study of Solid Tumor, is actively recruiting participants, sponsored by St. Jude Children's Research Hospital.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 25 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of the study is to find out the usefulness and safety of a dye called Indocyanine Green (ICG for short). This dye will be used to help the surgeon find lymph nodes draining solid tumors inside the abdomen that need to be removed. This may also help the surgeon to find if the cancer has moved to other lymph nodes outside of the known area. Primary Objectives * To determine the percentage of patients in whom Indocyanine Green (ICG)-guided sentinel lymph node (SLN) mapping was successful at the time of retroperitoneal lymph node dissection for staging of visceral solid tumors. * To determine the percentage of patients with grade 3 or higher adverse events related to ICG use.
Primary Outcome
The estimated percentage of ICG identification and its confidence interval (CI) based on the Pearson-Klopper method exact method will be calculated.
Conditions Studied
Interventions
- DRUG Indocyanine Green
Study Locations (3)
Illinois
- Lurie Children's Hospital - Chicago
Pennsylvania
- Children's Hospital of Pittsburgh of UPMC - Pittsburgh
Tennessee
- St. Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-10-24 |
| Est. Completion | 2026-12 |
| Phase | Early Phase 1 |
What NCT05645523 shows while recruiting
NCT05645523 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 222-participant average among 196 other Solid Tumor trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Indocyanine Green is the first listed.
NCT05645523 reports a single indexed study location in Illinois, Pennsylvania, Tennessee.
Frequently Asked Questions
What is clinical trial NCT05645523 about?
NCT05645523 is a clinical study titled "Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors". The purpose of the study is to find out the usefulness and safety of a dye called Indocyanine Green (ICG for short). This dye will be used to help the surgeon find lymph nodes draining solid tumors inside the abdomen that need to be removed. This may also help the surgeon to find if the cancer has m...
What is the current status of trial NCT05645523?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 25 participants. The study started on 2023-10-24. Estimated completion is 2026-12.
What conditions does trial NCT05645523 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT05645523?
The interventions under investigation include: Indocyanine Green (DRUG).
Who is sponsoring clinical trial NCT05645523?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05645523 being conducted?
This trial has 3 study locations across Illinois, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05645523's enrollment target sits among peer trials
25 167th of 196 higher than 28 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence
RECRUITING · Early Phase 1
-
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
RECRUITING · Early Phase 1
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI